Who are low-intensity statin plus ezetimibe's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-intensity-statin-plus-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

low-intensity statin plus ezetimibe — Competitive Intelligence Brief

low-intensity statin plus ezetimibe (low-intensity statin plus ezetimibe) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination lipid-lowering agent (statin + ezetimibe). Area: Cardiovascular.

marketed Combination lipid-lowering agent (statin + ezetimibe) HMG-CoA reductase (statin component); NPC1L1 transporter (ezetimibe component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

low-intensity statin plus ezetimibe (low-intensity statin plus ezetimibe) — Seung-Whan Lee, M.D., Ph.D.. A combination therapy that reduces LDL cholesterol through dual inhibition of cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
low-intensity statin plus ezetimibe TARGET	low-intensity statin plus ezetimibe	Seung-Whan Lee, M.D., Ph.D.	marketed	Combination lipid-lowering agent (statin + ezetimibe)	HMG-CoA reductase (statin component); NPC1L1 transporter (ezetimibe component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination lipid-lowering agent (statin + ezetimibe) class)

Seung-Whan Lee, M.D., Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low-intensity statin plus ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/low-intensity-statin-plus-ezetimibe. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab